 In 1989, a major scandal erupted involving the procedures used by the FDA to approve generic drugs for sale to the public.Charges of corruption in generic drug approval first emerged in 1988, in the course of an extensive congressional investigation into the FDA.The oversight subcommittee of the United States House Energy and Commerce Committee resulted from a complaint brought against the FDA by Mylan Laboratories Inc. of Pittsburgh.